PMID: 7518926Jul 19, 1994Paper

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75

Proceedings of the National Academy of Sciences of the United States of America
T YanoA V Schally

Abstract

Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer cell line were treated with potent luteinizing hormone (LH)-releasing hormone (LH-RH) antagonist SB-75 (Cetrorelix; [Ac-D-Nal(2)1, D-Phe(4 CI)2, D-Pal(3)3, D-Cit6, D-Ala10]LH-RH in which Ac-D-Nal(2) = N-acetyl-3-(2-naphthyl)-D-alanine, D-Phe(4CI) = 4-chloro-D-phenylalanine, D-Pal(3) = 3-(3-pyridyl)-D-alanine, and D-Cit = D-Citrulline) or with the agonist [D-Trp6]LH-RH. In the first experiment, SB-75 and [D-Trp6]LH-RH were administered in the form of microcapsules releasing 60 and 25 micrograms/day, respectively. In the second study, the analogs were given by daily s.c. injections in doses of 100 micrograms/day. In both experiments, tumor growth, as measured by reduction in tumor volume, percentage change in tumor volume, tumor burden, and increase in tumor doubling time, was significantly inhibited by treatment with SB-75 but not with [D-Trp6]LH-RH. Uterine and ovarian weights were reduced and serum LH levels decreased by administration of either analog. Chronic treatment with SB-75 greatly reduced the concentration of receptors for epidermal growth factor and insulin-like growth factor I in tumor cell membranes, a phenomenon that might be re...Continue Reading

References

Mar 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T Segal-AbramsonY Sharoni
Feb 1, 1991·Endocrine Reviews·B R Rao, B J Slotman
May 1, 1991·The Journal of Clinical Endocrinology and Metabolism·M A ThompsonL M Kaufman
Mar 21, 1990·Journal of the National Cancer Institute·B SzendeA V Schally
Sep 1, 1989·Journal of Clinical Pathology·K Y ChiuK K Wong
Nov 1, 1989·American Journal of Obstetrics and Gynecology·H W Bruckner, B T Motwani
Aug 1, 1989·European Journal of Obstetrics, Gynecology, and Reproductive Biology·W JägerN Lang
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M M Tomayko, C P Reynolds
Dec 1, 1989·Proceedings of the Society for Experimental Biology and Medicine·G SrkalovicA V Schally
Feb 1, 1989·European Journal of Cancer & Clinical Oncology·G EmonsR Knuppen
Mar 1, 1987·The Journal of Clinical Endocrinology and Metabolism·K A EidneR P Millar
Sep 1, 1980·Analytical Biochemistry·P J Munson, D Rodbard
Mar 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·T YanoA V Schally

❮ Previous
Next ❯

Citations

Dec 26, 2001·Journal of Inorganic Biochemistry·Katrien Noyelle, Herman Van Dael
May 29, 2003·Molecular and Cellular Endocrinology·Peter C K LeungXiao-Ming Zhu
Jan 28, 1999·Molecular and Cellular Endocrinology·N A RahmanI T Huhtaniemi
Jul 20, 2000·Journal of Chromatography. B, Biomedical Sciences and Applications·W J UnderbergJ C Waterval
Jan 12, 1999·Journal of Pharmaceutical and Biomedical Analysis·J L ReubsaetW J Underberg
Mar 18, 1999·Hematology/oncology Clinics of North America·G Emons, J J Kavanagh
Jun 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A JungwirthA V Schally
Apr 15, 2008·Trends in Endocrinology and Metabolism : TEM·G EmonsA V Schally
Dec 10, 1997·Journal of the National Cancer Institute·M MiyazakiP Armatis
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H ZhengS Fu
Nov 5, 2003·Reproductive Biology and Endocrinology : RB&E·Carsten Gründker, Günter Emons
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·M KovacsK Groot
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y S SchiffenbauerM Neeman
Apr 3, 2001·Expert Opinion on Investigational Drugs·P LimontaR M Moretti
Sep 8, 2005·Expert Opinion on Investigational Drugs·Askan Schultze-MosgauKlaus Diedrich
Dec 31, 2015·Human Reproduction Update·Roberto MaggiPatrizia Limonta
Jan 11, 2007·The Journal of Obstetrics and Gynaecology Research·Alice S T Wong, Peter C K Leung
Oct 31, 2008·The FEBS Journal·Lydia W T Cheung, Alice S T Wong
Oct 6, 2001·Frontiers in Neuroendocrinology·A V SchallyG Halmos
Jul 27, 1999·Gynecologic Oncology·J H KimS E Namkoong
Apr 8, 2016·Clinical Medicine Insights. Oncology·Ioannis A Voutsadakis
Aug 6, 2002·The Journal of Clinical Endocrinology and Metabolism·Roberta M MorettiPatrizia Limonta
Aug 22, 2017·Frontiers in Endocrinology·Carsten Gründker, Günter Emons
May 5, 2005·The Journal of Clinical Endocrinology and Metabolism·Kaushik MaitiJae Young Seong
Jul 11, 2012·Endocrine Reviews·Patrizia LimontaRoberta M Moretti
Mar 1, 1996·Cancer Control : Journal of the Moffitt Cancer Center·O BalatJ J Kavanagh
Jan 20, 2016·International Journal of Oncology·Arturo Aguilar-RojasGuadalupe Maya-Núñez
Mar 7, 2021·Cells·Carsten Gründker, Günter Emons

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.